Key result
Low-dose bendroflumethiazide was as effective as propranolol for blood pressure reduction over 10 years and resulted in fewer cases of overt diabetes (1.89% vs 9.43%).
Why the study?
Does low-dose bendroflumethiazide compared to propranolol induce diabetes or worsen metabolic variables in middle-aged men with mild to moderate hypertension?
Population
106 middle-aged men with mild to moderate hypertension (n=53 per group)
Comparison
Bendroflumethiazide 2.5-5 mg/day vs Propranolol 160-320 mg daily
Design
RCT, randomized
Follow-up
10 years
Authors
Loading...
Low-dose bendroflumethiazide may be preferred to propranolol in hypertensive men; challenges thiazide diabetogenicity concerns in long-term RCTs.
RCT (n=106)
Randomized
Does low-dose bendroflumethiazide compared to propranolol induce diabetes or worsen metabolic variables in middle-aged men with mild to moderate hypertension?
Absolute Event Rate: 1.89% vs 9.43%
Long-term low-dose bendroflumethiazide is as effective as propranolol for blood pressure reduction and does not increase the risk of developing diabetes in middle-aged hypertensive men.
Berglund et al. (1986) conducted an RCT in Mild to moderate hypertension (n=106). Bendroflumethiazide vs. Propranolol 160-320 mg daily was evaluated on Development of clinically overt diabetes. Low-dose bendroflumethiazide was as effective as propranolol for blood pressure reduction over 10 years and resulted in fewer cases of overt diabetes (1.89% vs 9.43%).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: